{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:12:46Z","timestamp":1793819566234,"version":"4.6.1"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41581-025-01036-y","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:02:37Z","timestamp":1767866557000},"page":"265-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-5700","authenticated-orcid":false,"given":"Radica Z.","family":"Alicic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1036_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000534071","volume":"148","author":"M Ying","year":"2024","unstructured":"Ying, M. et al. Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019. Nephron 148, 113\u2013123 (2024).","journal-title":"Nephron"},{"key":"1036_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. 12, 7\u201311 (2022).","journal-title":"Kidney Int. Suppl."},{"key":"1036_CR3","unstructured":"International Diabetes Federation. Diabetes Atlas 10th edn (International Diabetes Federation, 2021)."},{"key":"1036_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(18)32822-8","volume":"393","author":"BA Swinburn","year":"2019","unstructured":"Swinburn, B. A. et al. The global syndemic of obesity, undernutrition, and climate change: the Lancet Commission report. Lancet 393, 791\u2013846 (2019).","journal-title":"Lancet"},{"key":"1036_CR5","unstructured":"World Health Organization (WHO). Obesity and Overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2025)."},{"key":"1036_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018799","volume":"10","author":"NA Cameron","year":"2021","unstructured":"Cameron, N. A. et al. Quantifying the sex-race\/ethnicity-specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES. J. Am. Heart Assoc. 10, e018799\u00a0(2021).","journal-title":"J. Am. Heart Assoc."},{"key":"1036_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"Murray, C. J. L. et al. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease study 2019. Lancet 396, 1223\u20131249 (2020).","journal-title":"Lancet"},{"key":"1036_CR8","unstructured":"Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019) Covariates 1980\u20132019, https:\/\/ghdx.healthdata.org\/record\/global-burden-disease-study-2019-gbd-2019-covariates-1980-2019."},{"key":"1036_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","volume":"7","author":"A Okunogbe","year":"2022","unstructured":"Okunogbe, A. et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob. Health 7, e009773 (2022).","journal-title":"BMJ Glob. Health"},{"key":"1036_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2018.12.011","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos, S. A. & Mantzoros, C. S. Obesity: seize the day, fight the fat. Metab. Clin. Exp. 92, 1\u20135 (2019).","journal-title":"Metab. Clin. Exp."},{"key":"1036_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari, C. & Mantzoros, C. S. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metab. Clin. Exp. 133, 155217 (2022).","journal-title":"Metab. Clin. Exp."},{"key":"1036_CR12","doi-asserted-by":"publisher","unstructured":"Tuttle K. R. et al. Risks of kidney failure and death in a real-world population with diabetes. Clin. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.2215\/CJN.0000000857 (2025).","DOI":"10.2215\/CJN.0000000857"},{"key":"1036_CR13","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"ME Grams","year":"2023","unstructured":"Grams, M. E. et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA 330, 1266\u20131277 (2023).","journal-title":"JAMA"},{"key":"1036_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski, J., Floege, J., Fliser, D., Bohm, M. & Marx, N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143, 1157\u20131172 (2021).","journal-title":"Circulation"},{"key":"1036_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1159\/000528560","volume":"53","author":"X Li","year":"2022","unstructured":"Li, X. & Lindholm, B. Cardiovascular risk prediction in chronic kidney disease. Am. J. Nephrol. 53, 730\u2013739 (2022).","journal-title":"Am. J. Nephrol."},{"key":"1036_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1036_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013212\u00a0(2024).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR18","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/dom.14712","volume":"24","author":"VER Parker","year":"2022","unstructured":"Parker, V. E. R. et al. Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 24, 1360\u20131369 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","volume":"91","author":"MA Nauck","year":"1993","unstructured":"Nauck, M. A. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301\u2013307 (1993).","journal-title":"J. Clin. Invest."},{"key":"1036_CR20","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300\u20131304 (1987).","journal-title":"Lancet"},{"key":"1036_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1210\/jc.2010-2435","volume":"96","author":"JI Bagger","year":"2011","unstructured":"Bagger, J. I. et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96, 737\u2013745 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdi.12480","volume":"7","author":"RA Pederson","year":"2016","unstructured":"Pederson, R. A. & McIntosh, C. H. Discovery of gastric inhibitory polypeptide and its subsequent fate: personal reflections. J. Diabetes Investig. 7, 4\u20137 (2016).","journal-title":"J. Diabetes Investig."},{"key":"1036_CR23","first-page":"912","volume":"76","author":"MA Nauck","year":"1993","unstructured":"Nauck, M. A., Bartels, E., Orskov, C., Ebert, R. & Creutzfeldt, W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76, 912\u2013917 (1993).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR24","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/j.2040-4603.2019.tb00092.x","volume":"9","author":"JJ Holst","year":"2019","unstructured":"Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M. & Deacon, C. F. Physiology of the incretin hormones, GIP and GLP-1-regulation of release and posttranslational modifications. Compr. Physiol. 9, 1339\u20131381 (2019).","journal-title":"Compr. Physiol."},{"key":"1036_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic, R. Z., Cox, E. J., Neumiller, J. J. & Tuttle, K. R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227\u2013244 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"1036_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2337\/db18-0729","volume":"68","author":"MK Holt","year":"2019","unstructured":"Holt, M. K. et al. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes 68, 21\u201333 (2019).","journal-title":"Diabetes"},{"key":"1036_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Pfeiffer, A. F. H. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes. Metab. 23, 5\u201329 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2613.2011.00767.x","volume":"92","author":"AR Gunawardene","year":"2011","unstructured":"Gunawardene, A. R., Corfe, B. M. & Staton, C. A. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int. J. Exp. Pathol. 92, 219\u2013231 (2011).","journal-title":"Int. J. Exp. Pathol."},{"key":"1036_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/cne.902710405","volume":"271","author":"SL Jin","year":"1988","unstructured":"Jin, S. L. et al. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J. Comp. Neurol. 271, 519\u2013532 (1988).","journal-title":"J. Comp. Neurol."},{"key":"1036_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2024.171200","volume":"176","author":"NM Morrow","year":"2024","unstructured":"Morrow, N. M., Morissette, A. & Mulvihill, E. E. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut. Peptides 176, 171200 (2024).","journal-title":"Peptides"},{"key":"1036_CR31","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.cmet.2022.10.001","volume":"34","author":"ME Capozzi","year":"2022","unstructured":"Capozzi, M. E., D\u2019Alessio, D. A. & Campbell, J. E. The past, present, and future physiology and pharmacology of glucagon. Cell Metab. 34, 1654\u20131674 (2022).","journal-title":"Cell Metab."},{"key":"1036_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.regpep.2004.06.007","volume":"128","author":"CF Deacon","year":"2005","unstructured":"Deacon, C. F. What do we know about the secretion and degradation of incretin hormones? Regul. Pept. 128, 117\u2013124 (2005).","journal-title":"Regul. Pept."},{"key":"1036_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740\u2013756 (2018).","journal-title":"Cell Metab."},{"key":"1036_CR34","first-page":"786","volume":"82","author":"HJ Balks","year":"1997","unstructured":"Balks, H. J., Holst, J. J., von zur Muhlen, A. & Brabant, G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J. Clin. Endocrinol. Metab. 82, 786\u2013790 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD Muller","year":"2019","unstructured":"Muller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130 (2019).","journal-title":"Mol. Metab."},{"key":"1036_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.cmet.2017.06.003","volume":"26","author":"E Grasset","year":"2017","unstructured":"Grasset, E. et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric no-dependent and gut-brain axis mechanism. Cell Metab. 26, 278 (2017).","journal-title":"Cell Metab."},{"key":"1036_CR37","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.2513","volume":"17","author":"H Ellingsgaard","year":"2011","unstructured":"Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17, 1481\u20131489 (2011).","journal-title":"Nat. Med."},{"key":"1036_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-016-0330-8","volume":"15","author":"C Lebherz","year":"2016","unstructured":"Lebherz, C. et al. Interleukin-6 predicts inflammation-induced increase of glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. Cardiovasc. Diabetol. 15, 21 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"1036_CR39","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2337\/db14-0100","volume":"63","author":"F Kahles","year":"2014","unstructured":"Kahles, F. et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63, 3221\u20133229 (2014).","journal-title":"Diabetes"},{"key":"1036_CR40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/dom.12711","volume":"18","author":"F Kahles","year":"2016","unstructured":"Kahles, F. et al. Glucose-dependent insulinotropic peptide secretion is induced by inflammatory stimuli in an interleukin-1-dependent manner in mice. Diabetes Obes. Metab. 18, 1147\u20131151 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR41","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.celrep.2017.10.008","volume":"21","author":"LJ Lebrun","year":"2017","unstructured":"Lebrun, L. J. et al. Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep. 21, 1160\u20131168 (2017).","journal-title":"Cell Rep."},{"key":"1036_CR42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1006\/geno.1995.9937","volume":"29","author":"Y Yamada","year":"1995","unstructured":"Yamada, Y. et al. Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. Genomics 29, 773\u2013776 (1995).","journal-title":"Genomics"},{"key":"1036_CR43","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","volume":"89","author":"B Thorens","year":"1992","unstructured":"Thorens, B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl Acad. Sci. USA 89, 8641\u20138645 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1036_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal. Transduct. Target. Ther. 9, 234 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1036_CR45","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00207454.2021.1924707","volume":"133","author":"L Zhang","year":"2023","unstructured":"Zhang, L., Zhang, W. & Tian, X. The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases. Int. J. Neurosci. 133, 473\u2013491 (2023).","journal-title":"Int. J. Neurosci."},{"key":"1036_CR46","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1111\/dom.13369","volume":"20","author":"AC Meyer-Gerspach","year":"2018","unstructured":"Meyer-Gerspach, A. C. et al. Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: a pilot study. Diabetes Obes. Metab. 20, 2330\u20132338 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","volume":"20","author":"S Ansari","year":"2024","unstructured":"Ansari, S., Khoo, B. & Tan, T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 20, 447\u2013459 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1036_CR48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fendo.2018.00754","volume":"9","author":"EWL Sun","year":"2018","unstructured":"Sun, E. W. L., Martin, A. M., Young, R. L. & Keating, D. J. The regulation of peripheral metabolism by gut-derived hormones. Front. Endocrinol. 9, 754 (2018).","journal-title":"Front. Endocrinol."},{"key":"1036_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuroscience.2011.02.023","volume":"180","author":"IJ Llewellyn-Smith","year":"2011","unstructured":"Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M. & Trapp, S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 180, 111\u2013121 (2011).","journal-title":"Neuroscience"},{"key":"1036_CR50","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"Drucker, D. J. & Holst, J. J. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66, 1765\u20131779 (2023).","journal-title":"Diabetologia"},{"key":"1036_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR52","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR53","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280\u20131290 (2014).","journal-title":"Endocrinology"},{"key":"1036_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","volume":"141","author":"P Schlatter","year":"2007","unstructured":"Schlatter, P., Beglinger, C., Drewe, J. & Gutmann, H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul. Pept. 141, 120\u2013128 (2007).","journal-title":"Regul. Pept."},{"key":"1036_CR55","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"M Korner","year":"2007","unstructured":"Korner, M., Stockli, M., Waser, B. & Reubi, J. C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 48, 736\u2013743 (2007).","journal-title":"J. Nucl. Med."},{"key":"1036_CR56","doi-asserted-by":"publisher","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","volume":"301","author":"RO Crajoinas","year":"2011","unstructured":"Crajoinas, R. O. et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Renal Physiol. 301, F355\u2013F363 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1036_CR57","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1152\/ajprenal.00394.2015","volume":"310","author":"LX Farah","year":"2016","unstructured":"Farah, L. X. et al. The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am. J. Physiol. Renal Physiol. 310, F123\u2013F127 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1036_CR58","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1210\/jc.2003-031403","volume":"89","author":"JP Gutzwiller","year":"2004","unstructured":"Gutzwiller, J. P. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89, 3055\u20133061 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR59","doi-asserted-by":"publisher","first-page":"E664","DOI":"10.1210\/jc.2012-3855","volume":"98","author":"J Skov","year":"2013","unstructured":"Skov, J. et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 98, E664\u2013E671 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000094334","volume":"73","author":"JP Gutzwiller","year":"2006","unstructured":"Gutzwiller, J. P. et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73, 142\u2013150 (2006).","journal-title":"Digestion"},{"key":"1036_CR61","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","volume":"59","author":"L Tonneijck","year":"2016","unstructured":"Tonneijck, L. et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia 59, 1412\u20131421 (2016).","journal-title":"Diabetologia"},{"key":"1036_CR62","doi-asserted-by":"publisher","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","volume":"316","author":"L Tonneijck","year":"2019","unstructured":"Tonneijck, L. et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am. J. Physiol. Renal Physiol. 316, F231\u2013F240 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1036_CR63","doi-asserted-by":"publisher","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","volume":"303","author":"T Rieg","year":"2012","unstructured":"Rieg, T. et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Ren. Physiol. 303, F963\u2013F971 (2012).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1036_CR64","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1210\/clinem\/dgaa643","volume":"106","author":"A Asmar","year":"2021","unstructured":"Asmar, A. et al. The renal extraction and the natriuretic action of GLP-1 in Humans depend on interaction with the GLP-1 receptor. J. Clin. Endocrinol. Metab. 106, e11\u2013e19 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR65","doi-asserted-by":"publisher","first-page":"F854","DOI":"10.1152\/ajprenal.00258.2017","volume":"313","author":"SC Thomson","year":"2017","unstructured":"Thomson, S. C., Kashkouli, A., Liu, Z. Z. & Singh, P. Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin. Am. J. Physiol. Renal Physiol. 313, F854\u2013F858 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1036_CR66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","volume":"28","author":"VA Fonseca","year":"2014","unstructured":"Fonseca, V. A. et al. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J. Diabetes Complications 28, 399\u2013405 (2014).","journal-title":"J. Diabetes Complications"},{"key":"1036_CR67","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1126\/science.aar2131","volume":"360","author":"J Park","year":"2018","unstructured":"Park, J. et al. Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. Science 360, 758\u2013763 (2018).","journal-title":"Science"},{"key":"1036_CR68","doi-asserted-by":"publisher","first-page":"F50","DOI":"10.1152\/ajprenal.00077.2021","volume":"321","author":"BG Poll","year":"2021","unstructured":"Poll, B. G., Chen, L., Chou, C. L., Raghuram, V. & Knepper, M. A. Landscape of GPCR expression along the mouse nephron. Am. J. Physiol. Renal Physiol. 321, F50\u2013F68 (2021).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1036_CR69","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1681\/ASN.2020010071","volume":"31","author":"K Limbutara","year":"2020","unstructured":"Limbutara, K., Chou, C. L. & Knepper, M. A. Quantitative proteomics of all 14 renal tubule segments in rat. J. Am. Soc. Nephrol. 31, 1255\u20131266 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1036_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-019-0428-6","volume":"19","author":"Y Takeda","year":"2019","unstructured":"Takeda, Y. et al. Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes: a retrospective study from glucagon stimulation test. BMC Endocr. Disord. 19, 99 (2019).","journal-title":"BMC Endocr. Disord."},{"key":"1036_CR71","first-page":"F225","volume":"269","author":"M Ahloulay","year":"1995","unstructured":"Ahloulay, M., Dechaux, M., Laborde, K. & Bankir, L. Influence of glucagon on GFR and on urea and electrolyte excretion: direct and indirect effects. Am. J. Physiol. 269, F225\u2013F235 (1995).","journal-title":"Am. J. Physiol."},{"key":"1036_CR72","first-page":"F1003","volume":"257","author":"O Mercier","year":"1989","unstructured":"Mercier, O. et al. Effects of glucagon on H+-HCO3\u2013 transport in Henle\u2019s loop, distal tubule, and collecting ducts in the rat. Am. J. Physiol. 257, F1003\u2013F1014 (1989).","journal-title":"Am. J. Physiol."},{"key":"1036_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-018-0849-9","volume":"566","author":"S He","year":"2019","unstructured":"He, S. et al. Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease. Nature 566, 115\u2013119 (2019).","journal-title":"Nature"},{"key":"1036_CR74","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","volume":"34","author":"CK Wong","year":"2022","unstructured":"Wong, C. K. et al. Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation. Cell Metab. 34, 1514\u20131531.e1517 (2022).","journal-title":"Cell Metab."},{"key":"1036_CR75","doi-asserted-by":"publisher","first-page":"19641","DOI":"10.1074\/jbc.271.33.19641","volume":"271","author":"J Bubeck Wardenburg","year":"1996","unstructured":"Bubeck Wardenburg, J. et al. Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. J. Biol. Chem. 271, 19641\u201319644 (1996).","journal-title":"J. Biol. Chem."},{"key":"1036_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/bj20021637","volume":"371","author":"T Mustelin","year":"2003","unstructured":"Mustelin, T. & Tasken, K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J. 371, 15\u201327 (2003).","journal-title":"Biochem. J."},{"key":"1036_CR77","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","volume":"54","author":"R Kodera","year":"2011","unstructured":"Kodera, R. et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54, 965\u2013978 (2011).","journal-title":"Diabetologia"},{"key":"1036_CR78","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ni1008-1091","volume":"9","author":"TS Heng","year":"2008","unstructured":"Heng, T. S., Painter, M. W. & Immunological Genome Project, C The immunological genome project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091\u20131094 (2008).","journal-title":"Nat. Immunol."},{"key":"1036_CR79","doi-asserted-by":"publisher","first-page":"F878","DOI":"10.1152\/ajprenal.00590.2014","volume":"308","author":"Y Higashijima","year":"2015","unstructured":"Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S. & Nangaku, M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am. J. Physiol. Renal Physiol. 308, F878\u2013F887 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1036_CR80","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s42255-018-0001-z","volume":"1","author":"FD Mantelmacher","year":"2019","unstructured":"Mantelmacher, F. D. et al. GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8\/A9. Nat. Metab. 1, 58\u201369 (2019).","journal-title":"Nat. Metab."},{"key":"1036_CR81","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/diab.39.5.634","volume":"39","author":"SE Kahn","year":"1990","unstructured":"Kahn, S. E. et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39, 634\u2013638 (1990).","journal-title":"Diabetes"},{"key":"1036_CR82","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1055\/s-2007-1003714","volume":"23","author":"K Inoue","year":"1991","unstructured":"Inoue, K., Hisatomi, A., Umeda, F. & Nawata, H. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas. Horm. Metab. Res. 23, 407\u2013409 (1991).","journal-title":"Horm. Metab. Res."},{"key":"1036_CR83","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1152\/physrev.00042.2009","volume":"91","author":"P Westermark","year":"2011","unstructured":"Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795\u2013826 (2011).","journal-title":"Physiol. Rev."},{"key":"1036_CR84","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G. & Roth, J. D. Amylin: pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67, 564\u2013600 (2015).","journal-title":"Pharmacol. Rev."},{"key":"1036_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm9609","volume":"375","author":"J Cao","year":"2022","unstructured":"Cao, J. et al. A structural basis for amylin receptor phenotype. Science 375, eabm9609 (2022).","journal-title":"Science"},{"key":"1036_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2022.105965","volume":"172","author":"TA Lutz","year":"2022","unstructured":"Lutz, T. A. Creating the amylin story. Appetite 172, 105965 (2022).","journal-title":"Appetite"},{"key":"1036_CR87","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcpt.13427","volume":"127","author":"HL Zakariassen","year":"2020","unstructured":"Zakariassen, H. L., John, L. M. & Lutz, T. A. Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. Basic. Clin. Pharmacol. Toxicol. 127, 163\u2013177 (2020).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"1036_CR88","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/ijms25031517","volume":"25","author":"S Erzen","year":"2024","unstructured":"Erzen, S., Tonin, G., Jurisic Erzen, D. & Klen, J. Amylin, another important neuroendocrine hormone for the treatment of diabesity. Int. J. Mol. Sci. 25, 1517 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1036_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2020.112992","volume":"223","author":"B Coester","year":"2020","unstructured":"Coester, B., Foll, C. L. & Lutz, T. A. Viral depletion of calcitonin receptors in the area postrema: a proof-of-concept study. Physiol. Behav. 223, 112992 (2020).","journal-title":"Physiol. Behav."},{"key":"1036_CR90","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/1389450053174596","volume":"6","author":"TA Lutz","year":"2005","unstructured":"Lutz, T. A. Pancreatic amylin as a centrally acting satiating hormone. Curr. Drug. Targets 6, 181\u2013189 (2005).","journal-title":"Curr. Drug. Targets"},{"key":"1036_CR91","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","volume":"13","author":"CM Mack","year":"2011","unstructured":"Mack, C. M. et al. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes Obes. Metab. 13, 1105\u20131113 (2011).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR92","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.physbeh.2010.03.001","volume":"100","author":"CS Potes","year":"2010","unstructured":"Potes, C. S. & Lutz, T. A. Brainstem mechanisms of amylin-induced anorexia. Physiol. Behav. 100, 511\u2013518 (2010).","journal-title":"Physiol. Behav."},{"key":"1036_CR93","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1073\/pnas.0706473105","volume":"105","author":"JD Roth","year":"2008","unstructured":"Roth, J. D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257\u20137262 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1036_CR94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1210\/en.2009-0546","volume":"151","author":"VF Turek","year":"2010","unstructured":"Turek, V. F. et al. Mechanisms of amylin\/leptin synergy in rodent models. Endocrinology 151, 143\u2013152 (2010).","journal-title":"Endocrinology"},{"key":"1036_CR95","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/ejn.13163","volume":"43","author":"CG Liberini","year":"2016","unstructured":"Liberini, C. G. et al. Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons. Eur. J. Neurosci. 43, 653\u2013661 (2016).","journal-title":"Eur. J. Neurosci."},{"key":"1036_CR96","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2337\/db14-0645","volume":"64","author":"C Le Foll","year":"2015","unstructured":"Le Foll, C. et al. Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling. Diabetes 64, 1621\u20131631 (2015).","journal-title":"Diabetes"},{"key":"1036_CR97","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.1103160","volume":"306","author":"U Ozcan","year":"2004","unstructured":"Ozcan, U. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457\u2013461 (2004).","journal-title":"Science"},{"key":"1036_CR98","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840\u2013846 (2006).","journal-title":"Nature"},{"key":"1036_CR99","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","volume":"19","author":"A Mitrofanova","year":"2023","unstructured":"Mitrofanova, A., Merscher, S. & Fornoni, A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat. Rev. Nephrol. 19, 629\u2013645 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1036_CR100","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1152\/physrev.00034.2018","volume":"99","author":"SN Saxton","year":"2019","unstructured":"Saxton, S. N., Clark, B. J., Withers, S. B., Eringa, E. C. & Heagerty, A. M. Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue. Physiol. Rev. 99, 1701\u20131763 (2019).","journal-title":"Physiol. Rev."},{"key":"1036_CR101","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","volume":"15","author":"JE Hall","year":"2019","unstructured":"Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat. Rev. Nephrol. 15, 367\u2013385 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"1036_CR102","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615\u20131625 (2005).","journal-title":"Diabetes"},{"key":"1036_CR103","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0014-5793(00)02395-4","volume":"488","author":"C Weigert","year":"2001","unstructured":"Weigert, C., Brodbeck, K., Lehmann, R., Haring, H. U. & Schleicher, E. D. Overexpression of glutamine:fructose-6-phosphate-amidotransferase induces transforming growth factor-beta1 synthesis in NIH-3T3 fibroblasts. FEBS Lett. 488, 95\u201399 (2001).","journal-title":"FEBS Lett."},{"key":"1036_CR104","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1096\/fj.201601116R","volume":"31","author":"DK Deb","year":"2017","unstructured":"Deb, D. K., Bao, R. & Li, Y. C. Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney. FASEB J. 31, 2065\u20132075 (2017).","journal-title":"FASEB J."},{"key":"1036_CR105","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1091\/mbc.e14-03-0800","volume":"25","author":"CG Miller","year":"2014","unstructured":"Miller, C. G., Pozzi, A., Zent, R. & Schwarzbauer, J. E. Effects of high glucose on integrin activity and fibronectin matrix assembly by mesangial cells. Mol. Biol. Cell 25, 2342\u20132350 (2014).","journal-title":"Mol. Biol. Cell"},{"key":"1036_CR106","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2337\/dc10-0013","volume":"33","author":"RJ Wright","year":"2010","unstructured":"Wright, R. J. et al. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 33, 1591\u20131597 (2010).","journal-title":"Diabetes Care"},{"key":"1036_CR107","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.2337\/dc12-2469","volume":"36","author":"A Ceriello","year":"2013","unstructured":"Ceriello, A. et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36, 2346\u20132350 (2013).","journal-title":"Diabetes Care"},{"key":"1036_CR108","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.2337\/diabetes.51.12.3532","volume":"51","author":"M Morcos","year":"2002","unstructured":"Morcos, M. et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51, 3532\u20133544 (2002).","journal-title":"Diabetes"},{"key":"1036_CR109","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/01.ASN.0000065100.17349.CA","volume":"14","author":"T Wendt","year":"2003","unstructured":"Wendt, T. et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 14, 1383\u20131395 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1036_CR110","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus, A. et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83, 876\u2013886 (2005).","journal-title":"J. Mol. Med."},{"key":"1036_CR111","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cmet.2013.04.001","volume":"17","author":"PR Nagareddy","year":"2013","unstructured":"Nagareddy, P. R. et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 17, 695\u2013708 (2013).","journal-title":"Cell Metab."},{"key":"1036_CR112","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.kint.2018.10.041","volume":"95","author":"T Chen","year":"2019","unstructured":"Chen, T., Cao, Q., Wang, Y. & Harris, D. C. H. M2 macrophages in kidney disease: biology, therapies, and perspectives. Kidney Int. 95, 760\u2013773 (2019).","journal-title":"Kidney Int."},{"key":"1036_CR113","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1681\/ASN.2004070612","volume":"16","author":"FY Chow","year":"2005","unstructured":"Chow, F. Y., Nikolic-Paterson, D. J., Ozols, E., Atkins, R. C. & Tesch, G. H. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db\/db mice. J. Am. Soc. Nephrol. 16, 1711\u20131722 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1036_CR114","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00125-006-0497-8","volume":"50","author":"FY Chow","year":"2007","unstructured":"Chow, F. Y. et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db\/db mice. Diabetologia 50, 471\u2013480 (2007).","journal-title":"Diabetologia"},{"key":"1036_CR115","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-981-13-8871-2_4","volume":"1165","author":"LF Zeng","year":"2019","unstructured":"Zeng, L. F., Xiao, Y. & Sun, L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv. Exp. Med. Biol. 1165, 49\u201379 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1036_CR116","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/33340","volume":"392","author":"M Baggiolini","year":"1998","unstructured":"Baggiolini, M. Chemokines and leukocyte traffic. Nature 392, 565\u2013568 (1998).","journal-title":"Nature"},{"key":"1036_CR117","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang, S. C. W. & Yiu, W. H. Innate immunity in diabetic kidney disease. Nat. Rev. Nephrol. 16, 206\u2013222 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1036_CR118","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","volume":"36","author":"CK Wong","year":"2024","unstructured":"Wong, C. K. et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 36, 130\u2013143 e135 (2024).","journal-title":"Cell Metab."},{"key":"1036_CR119","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/kisup.2014.5","volume":"4","author":"WH Yiu","year":"2014","unstructured":"Yiu, W. H., Lin, M. & Tang, S. C. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int. Suppl. 4, 20\u201325 (2014).","journal-title":"Kidney Int. Suppl."},{"key":"1036_CR120","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1681\/ASN.2010111210","volume":"23","author":"M Lin","year":"2012","unstructured":"Lin, M. et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol.23, 86\u2013102 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1036_CR121","volume":"33","author":"G Huang","year":"2023","unstructured":"Huang, G., Zhang, Y., Zhang, Y. & Ma, Y. Chronic kidney disease and NLRP3 inflammasome: pathogenesis, development and targeted therapeutic strategies. Biochem. Biophys. Rep. 33, 101417\u00a0(2023).","journal-title":"Biochem. Biophys. Rep."},{"key":"1036_CR122","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ki.2014.271","volume":"87","author":"K Shahzad","year":"2015","unstructured":"Shahzad, K. et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 87, 74\u201384 (2015).","journal-title":"Kidney Int."},{"key":"1036_CR123","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.1184003","volume":"327","author":"K Schroder","year":"2010","unstructured":"Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296\u2013300 (2010).","journal-title":"Science"},{"key":"1036_CR124","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nri2725","volume":"10","author":"J Tschopp","year":"2010","unstructured":"Tschopp, J. & Schroder, K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. 10, 210\u2013215 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1036_CR125","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.kint.2022.06.010","volume":"102","author":"K Shahzad","year":"2022","unstructured":"Shahzad, K. et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. Kidney Int. 102, 766\u2013779 (2022).","journal-title":"Kidney Int."},{"key":"1036_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes \u2014 state-of-the-art. Mol. Metab. 46, 101102 (2021).","journal-title":"Mol. Metab."},{"key":"1036_CR127","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13435","volume":"23","author":"J Iqbal","year":"2022","unstructured":"Iqbal, J. et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus \u2014 a systematic review and meta-analysis of randomized control trials. Obes. Rev. 23, e13435 (2022).","journal-title":"Obes. Rev."},{"key":"1036_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384, e076410 (2024).","journal-title":"BMJ"},{"key":"1036_CR129","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike, Z. Z. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes. Metab. 19, 524\u2013536 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR130","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1042\/CS20171299","volume":"132","author":"JG Boyle","year":"2018","unstructured":"Boyle, J. G., Livingstone, R. & Petrie, J. R. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clin. Sci. 132, 1699\u20131709 (2018).","journal-title":"Clin. Sci."},{"key":"1036_CR131","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M. & Drucker, D. J. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136, 849\u2013870 (2017).","journal-title":"Circulation"},{"key":"1036_CR132","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.14443","volume":"23","author":"JFE Mann","year":"2021","unstructured":"Mann, J. F. E. et al. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes. Metab. 23, 2058\u20132066 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR133","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839\u2013848 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR134","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/dc24-1773","volume":"48","author":"EM Apperloo","year":"2025","unstructured":"Apperloo, E. M. et al. Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1-5 clinical trials. Diabetes Care 48, 430\u2013436\u00a0(2025).","journal-title":"Diabetes Care"},{"key":"1036_CR135","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2337\/dc22-1889","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the step 1, 2, and 3 trials. Diabetes Care 46, 801\u2013810 (2023).","journal-title":"Diabetes Care"},{"key":"1036_CR136","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc13-2618","volume":"37","author":"A Ceriello","year":"2014","unstructured":"Ceriello, A. et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 37, 1938\u20131943 (2014).","journal-title":"Diabetes Care"},{"key":"1036_CR137","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1210\/jc.2011-1508","volume":"97","author":"A Chaudhuri","year":"2012","unstructured":"Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198\u2013207 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR138","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 105, 132\u2013149 (2024).","journal-title":"Kidney Int."},{"key":"1036_CR139","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1159\/000509418","volume":"144","author":"ME Ougaard","year":"2020","unstructured":"Ougaard, M. E. et al. Liraglutide improves the kidney function in a murine model of chronic kidney disease. Nephron 144, 595\u2013606 (2020).","journal-title":"Nephron"},{"key":"1036_CR140","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/annrheumdis-2017-212935","volume":"77","author":"PC Grayson","year":"2018","unstructured":"Grayson, P. C. et al. Metabolic pathways and immunometabolism in rare kidney diseases. Ann. Rheum. Dis. 77, 1226\u20131233 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1036_CR141","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cmet.2023.12.024","volume":"36","author":"MY Wang","year":"2024","unstructured":"Wang, M. Y. et al. Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease. Cell Metab. 36, 575\u2013597 e577 (2024).","journal-title":"Cell Metab."},{"key":"1036_CR142","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR143","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12020-014-0519-0","volume":"50","author":"M Zavattaro","year":"2015","unstructured":"Zavattaro, M. et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50, 620\u2013626 (2015).","journal-title":"Endocrine"},{"key":"1036_CR144","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2337\/dc14-2883","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies, M. J. et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39, 222\u2013230 (2016).","journal-title":"Diabetes Care"},{"key":"1036_CR145","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamainternmed.2023.1487","volume":"183","author":"DJ Wexler","year":"2023","unstructured":"Wexler, D. J. et al. Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the grade randomized clinical trial. JAMA Intern. Med. 183, 705\u2013714 (2023).","journal-title":"JAMA Intern. Med."},{"key":"1036_CR146","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2215\/CJN.0000000587","volume":"20","author":"JJ Neumiller","year":"2024","unstructured":"Neumiller, J. J. et al. Kidney outcomes with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas in type 2 diabetes and moderate cardiovascular risk. Clin. J. Am. Soc. Nephrol. 20, 206\u2013217\u00a0(2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1036_CR147","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636\u20131664 (2023).","journal-title":"Circulation"},{"key":"1036_CR148","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247\u20132257 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR149","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859\u2013869 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1036_CR150","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR151","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/dc19-1065","volume":"43","author":"MA Bethel","year":"2019","unstructured":"Bethel, M. A. et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care 43, 446\u2013452 (2019).","journal-title":"Diabetes Care"},{"key":"1036_CR152","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.diabres.2019.05.001","volume":"153","author":"MHA Muskiet","year":"2019","unstructured":"Muskiet, M. H. A. et al. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial. Diabetes Res. Clin. Pract. 153, 14\u201322 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1036_CR153","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"1036_CR154","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131\u2013138 (2019).","journal-title":"Lancet"},{"key":"1036_CR155","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605\u2013617 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1036_CR156","doi-asserted-by":"publisher","first-page":"254","DOI":"10.34067\/KID.0005852020","volume":"2","author":"KR Tuttle","year":"2021","unstructured":"Tuttle, K. R. et al. Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis. Kidney360 2, 254\u2013262 (2021).","journal-title":"Kidney360"},{"key":"1036_CR157","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519\u20131529 (2018).","journal-title":"Lancet"},{"key":"1036_CR158","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896\u2013907 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR159","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR160","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","volume":"9","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial. Kidney Int. Rep. 9, 2006\u20132015 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1036_CR161","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR162","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire, D. K. et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 392, 2001\u20132012\u00a0(2025).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR163","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774\u2013785 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1036_CR164","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2337\/dc23-0261","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on cystatin c-based kidney function: a SURPASS-4 post hoc analysis. Diabetes Care 46, 1501\u20131506 (2023).","journal-title":"Diabetes Care"},{"key":"1036_CR165","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1681\/ASN.0000000764","volume":"36","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink, H. J. L. et al. Kidney parameters with tirzepatide in obesity with or without type 2 diabetes. J. Am. Soc. Nephrol. 36, 2190\u20132200 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1036_CR166","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman, A. M. et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145, 575\u2013585 (2022).","journal-title":"Circulation"},{"key":"1036_CR167","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","volume":"103","author":"KR Tuttle","year":"2023","unstructured":"Tuttle, K. R. et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 103, 772\u2013781 (2023).","journal-title":"Kidney Int."},{"key":"1036_CR168","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ndt\/gfae150","volume":"40","author":"EM Apperloo","year":"2025","unstructured":"Apperloo, E. M. et al. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrol. Dial. Transpl. 40, 352\u2013359\u00a0(2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1036_CR169","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1036_CR170","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13, 15\u201328 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1036_CR171","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2215\/CJN.0000000584","volume":"20","author":"L Mendonca","year":"2024","unstructured":"Mendonca, L., Moura, H., Chaves, P. C., Neves, J. S. & Ferreira, J. P. The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials. Clin. J. Am. Soc. Nephrol. 20, 159\u2013168\u00a0(2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1036_CR172","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc24-1533","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 48, 846\u2013859 (2025).","journal-title":"Diabetes Care"},{"key":"1036_CR173","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1111\/dom.15834","volume":"26","author":"L Chu","year":"2024","unstructured":"Chu, L., Bradley, R. M., Auerbach, P. & Abitbol, A. Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: the impact GLP-1 CKD study. Diabetes Obes. Metab. 26, 4674\u20134683 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54009-3","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease. Nat. Commun. 15, 10623 (2024).","journal-title":"Nat. Commun."},{"key":"1036_CR175","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/dom.15194","volume":"25","author":"SB Nicholas","year":"2023","unstructured":"Nicholas, S. B. et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes. Metab. 25, 2970\u20132979 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR176","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1111\/dom.15872","volume":"26","author":"MCH Lassen","year":"2024","unstructured":"Lassen, M. C. H. et al. Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: a nationwide registry study. Diabetes Obes. Metab. 26, 5239\u20135250 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR177","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/dom.15038","volume":"25","author":"H Jung","year":"2023","unstructured":"Jung, H. et al. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: a retrospective analysis of the diabetes prospective follow-up registry. Diabetes Obes. Metab. 25, 1813\u20131822 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR178","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV Sikirica","year":"2017","unstructured":"Sikirica, M. V. et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab. Syndr. Obes. 10, 403\u2013412 (2017).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"1036_CR179","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/13696998.2025.2459529","volume":"28","author":"P McEwan","year":"2025","unstructured":"McEwan, P. et al. Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. J. Med. Econ. 28, 268\u2013278 (2025).","journal-title":"J. Med. Econ."},{"key":"1036_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110625","volume":"198","author":"CT Yang","year":"2023","unstructured":"Yang, C. T., Yao, W. Y., Ou, H. T. & Kuo, S. Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: a model-based cost-effectiveness analysis using real-world data. Diabetes Res. Clin. Pract. 198, 110625 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1036_CR181","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951\u2013962 (2025).","journal-title":"Nat. Med."},{"key":"1036_CR182","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","volume":"20","author":"DH van Raalte","year":"2024","unstructured":"van Raalte, D. H. et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat. Rev. Nephrol. 20, 433\u2013446\u00a0(2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1036_CR183","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.kint.2023.11.025","volume":"105","author":"EL Fu","year":"2024","unstructured":"Fu, E. L. et al. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes. Kidney Int. 105, 618\u2013628 (2024).","journal-title":"Kidney Int."},{"key":"1036_CR184","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078483","volume":"385","author":"EL Fu","year":"2024","unstructured":"Fu, E. L. et al. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ 385, e078483 (2024).","journal-title":"BMJ"},{"key":"1036_CR185","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamainternmed.2024.3806","volume":"184","author":"T Huang","year":"2024","unstructured":"Huang, T. et al. GLP-1RA vs DPP-4i use and rates of hyperkalemia and RAS blockade discontinuation in type 2 diabetes. JAMA Intern. Med. 184, 1195\u20131203 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1036_CR186","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","volume":"40","author":"RZ Alicic","year":"2025","unstructured":"Alicic, R. Z., Neumiller, J. J. & Tuttle, K. R. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol. Dial. Transpl. 40, i3\u2013i17 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1036_CR187","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. 30, 2849\u20132856 (2024).","journal-title":"Nat. Med."},{"key":"1036_CR188","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dom.14883","volume":"25","author":"P Rossing","year":"2023","unstructured":"Rossing, P. et al. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes. Metab. 25, 407\u2013416 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"1036_CR189","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/ndt\/gfaf114","volume":"40","author":"DZI Cherney","year":"2025","unstructured":"Cherney, D. Z. I. et al. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transpl. 40, 2182\u20132192\u00a0(2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1036_CR190","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton, S. et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. 389, 877\u2013888 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR191","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock, J. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N. Engl. J. Med. 393, 1065\u20131076\u00a0(2025).","journal-title":"N. Engl. J. Med."},{"key":"1036_CR192","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","volume":"406","author":"A Gasiorek","year":"2025","unstructured":"Gasiorek, A. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet 406, 135\u2013148 (2025).","journal-title":"Lancet"},{"key":"1036_CR193","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","volume":"406","author":"K Dahl","year":"2025","unstructured":"Dahl, K. et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study. Lancet 406, 149\u2013162 (2025).","journal-title":"Lancet"},{"key":"1036_CR194","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","volume":"106","author":"V Selvarajah","year":"2024","unstructured":"Selvarajah, V. et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 106, 1170\u20131180 (2024).","journal-title":"Kidney Int."},{"key":"1036_CR195","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle, K. R. et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw. Open. 2, e1918169 (2019).","journal-title":"JAMA Netw. Open."},{"key":"1036_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1558-9","volume":"20","author":"KC Norris","year":"2019","unstructured":"Norris, K. C. et al. Rationale and design of a multicenter chronic kidney disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD. BMC Nephrol. 20, 416 (2019).","journal-title":"BMC Nephrol."},{"key":"1036_CR197","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ndt\/gfac283","volume":"38","author":"R Nee","year":"2023","unstructured":"Nee, R., Yuan, C. M., Narva, A. S., Yan, G. & Norris, K. C. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol. Dial. Transpl. 38, 532\u2013541 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1036_CR198","unstructured":"Exenatide injection. Prescribing information (Amneal Pharmaceuticals, 2025)."},{"key":"1036_CR199","unstructured":"Liraglutide (Victoza) injection. Prescribing information (Novo Nordisk, 2025)."},{"key":"1036_CR200","unstructured":"Liraglutide (Saxenda) injection. Prescribing information (Novo Nordisk, 2025)."},{"key":"1036_CR201","unstructured":"Exenatide extended-release (Bydureon BCise) injectable suspension. Prescribing information (AstraZeneca Pharmaceuticals, 2025)."},{"key":"1036_CR202","unstructured":"Dulaglutide (Trulicity) injection. Prescribing information (Eli Lilly, 2024)."},{"key":"1036_CR203","unstructured":"Semaglutide (Ozempic) injection. Prescribing information (Novo Nordisk, 2025)."},{"key":"1036_CR204","unstructured":"Semaglutide (Wegovy) injection. Prescribing information (Novo Nordisk, 2025)."},{"key":"1036_CR205","unstructured":"Semaglutide (Rybelsus) tablets. Prescribing information (Novo Nordisk, 2025)."},{"key":"1036_CR206","unstructured":"Tirzepatide (Mounjaro) injection. Prescribing information (Eli Lilly, 2025)."},{"key":"1036_CR207","unstructured":"Tirzepatide (Zepbound) injection. Prescribing information (Eli Lilly, 2025)."},{"key":"1036_CR208","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato, S. et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398, 1811\u20131824 (2021).","journal-title":"Lancet"},{"key":"1036_CR209","doi-asserted-by":"publisher","first-page":"18827","DOI":"10.1016\/S0021-9258(17)32241-X","volume":"269","author":"JJ Holst","year":"1994","unstructured":"Holst, J. J. et al. Proglucagon processing in porcine and human pancreas. J. Biol. Chem. 269, 18827\u201318833 (1994).","journal-title":"J. Biol. Chem."},{"key":"1036_CR210","doi-asserted-by":"publisher","first-page":"13475","DOI":"10.1016\/S0021-9258(18)68261-4","volume":"263","author":"DJ Drucker","year":"1988","unstructured":"Drucker, D. J. & Asa, S. Glucagon gene expression in vertebrate brain. J. Biol. Chem. 263, 13475\u201313478 (1988).","journal-title":"J. Biol. Chem."},{"key":"1036_CR211","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1177\/002215540205001108","volume":"50","author":"GM Portela-Gomes","year":"2002","unstructured":"Portela-Gomes, G. M. & Stridsberg, M. Chromogranin A in the human gastrointestinal tract: an immunocytochemical study with region-specific antibodies. J. Histochem. Cytochem. 50, 1487\u20131492 (2002).","journal-title":"J. Histochem. Cytochem."},{"key":"1036_CR212","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0167-0115(03)00125-3","volume":"114","author":"K Mortensen","year":"2003","unstructured":"Mortensen, K., Christensen, L. L., Holst, J. J. & Orskov, C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114, 189\u2013196 (2003).","journal-title":"Regul. Pept."},{"key":"1036_CR213","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1074\/jbc.M601203200","volume":"281","author":"R Ugleholdt","year":"2006","unstructured":"Ugleholdt, R. et al. Prohormone convertase 1\/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J. Biol. Chem. 281, 11050\u201311057 (2006).","journal-title":"J. Biol. Chem."},{"key":"1036_CR214","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131\u20132157 (2007).","journal-title":"Gastroenterology"},{"key":"1036_CR215","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nri3007","volume":"11","author":"H Cheroutre","year":"2011","unstructured":"Cheroutre, H., Lambolez, F. & Mucida, D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat. Rev. Immunol. 11, 445\u2013456 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"1036_CR216","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/db20-0262","volume":"69","author":"SE Martchenko","year":"2020","unstructured":"Martchenko, S. E. et al. Circadian GLP-1 Secretion in mice is dependent on the intestinal microbiome for maintenance of diurnal metabolic homeostasis. Diabetes 69, 2589\u20132602 (2020).","journal-title":"Diabetes"},{"key":"1036_CR217","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41564-021-00880-5","volume":"6","author":"HS Yoon","year":"2021","unstructured":"Yoon, H. S. et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat. Microbiol. 6, 563\u2013573 (2021).","journal-title":"Nat. Microbiol."},{"key":"1036_CR218","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-physiol-021115-105439","volume":"78","author":"FM Gribble","year":"2016","unstructured":"Gribble, F. M. & Reimann, F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu. Rev. Physiol. 78, 277\u2013299 (2016).","journal-title":"Annu. Rev. Physiol."},{"key":"1036_CR219","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1210\/jc.2002-021873","volume":"88","author":"T Vilsboll","year":"2003","unstructured":"Vilsboll, T. et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88, 2706\u20132713 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1036_CR220","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrgastro.2013.180","volume":"10","author":"JB Furness","year":"2013","unstructured":"Furness, J. B., Rivera, L. R., Cho, H. J., Bravo, D. M. & Callaghan, B. The gut as a sensory organ. Nat. Rev. Gastroenterol. Hepatol. 10, 729\u2013740 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1036_CR221","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41574-019-0168-8","volume":"15","author":"FM Gribble","year":"2019","unstructured":"Gribble, F. M. & Reimann, F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. Nat. Rev. Endocrinol. 15, 226\u2013237 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1036_CR222","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/mi.2017.73","volume":"11","author":"JJ Worthington","year":"2018","unstructured":"Worthington, J. J., Reimann, F. & Gribble, F. M. Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity. Mucosal Immunol. 11, 3\u201320 (2018).","journal-title":"Mucosal Immunol."},{"key":"1036_CR223","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2337\/db08-1328","volume":"58","author":"CC Berthier","year":"2009","unstructured":"Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469\u2013477 (2009).","journal-title":"Diabetes"},{"key":"1036_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/srep18822","volume":"6","author":"Y Peng","year":"2016","unstructured":"Peng, Y. et al. AGE-RAGE signal generates a specific NF-\u03baB RelA \u201cbarcode\u201d that directs collagen I expression. Sci. Rep. 6, 18822 (2016).","journal-title":"Sci. Rep."},{"key":"1036_CR225","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8637138","volume":"2017","author":"C Qi","year":"2017","unstructured":"Qi, C., Mao, X., Zhang, Z. & Wu, H. Classification and differential diagnosis of diabetic nephropathy. J. Diabetes Res. 2017, 8637138 (2017).","journal-title":"J. Diabetes Res."},{"key":"1036_CR226","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ki.2013.427","volume":"85","author":"H Fujita","year":"2014","unstructured":"Fujita, H. et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 85, 579\u2013589 (2014).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01036-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:01:51Z","timestamp":1774270911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":226,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01036-y","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"13 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.Z.A. is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from Travere Therapeutics Inc, the Doris Duke Charitable Foundation, Bayer AG, AstraZeneca, Novo Nordisk, The George Institute for Global Health, CareDx and KBP BioSciences, and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals and Eli Lilly. J.J.N. is supported by NIH research grant OT2OD032581 and a research grant from the American College of Clinical Pharmacy, reports consulting fees from Bayer AG, Sanofi, Boehringer Ingelheim, Eli Lilly and Proteomics International, reports payments for lectures from Dexcom and Med Learning Group and serves on the Board of Directors for the American Diabetes Association. K.R.T. is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264. She has also received investigator-initiated grant support from Travere Therapeutics Inc, Bayer, the Doris Duke Charitable Foundation and Breakthrough T1D. She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Novo Nordisk, Travere Therapeutics Inc, ProKidney and Alnylam; and speaker fees from Novo Nordisk Boehringer Ingelheim and Bayer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}